Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by

Johanna M Schwingel1, Katie J Edwards, Andrew D Cox

  • 1Department of Microbiology and Immunology, University at Buffalo, Buffalo, NY 14214, USA.

Infection and Immunity
|August 5, 2009
PubMed

Insights

This study investigated human antibody responses to Moraxella catarrhalis lipooligosaccharides (LOS) in COPD patients. Findings reveal varied antibody development against LOS epitopes during natural infection, crucial for vaccine development.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccine Development

Background:

  • Moraxella catarrhalis causes otitis media and COPD exacerbations.
  • No vaccine currently exists for M. catarrhalis.
  • Understanding human immune responses to M. catarrhalis is vital for vaccine design.

Purpose of the Study:

  • To analyze the human antibody response to M. catarrhalis lipooligosaccharides (LOS) during natural infection.
  • To characterize antibody development against specific LOS regions and serotypes.
  • To assess variability in immune responses among patients.

Main Methods:

  • Utilized a lipooligosaccharide (LOS)-based enzyme-linked immunosorbent assay (ELISA).
  • Included three major M. catarrhalis serotypes and truncated LOS mutants.
  • Compared serum samples from chronic obstructive pulmonary disease (COPD) patients before and after M. catarrhalis infection.

Main Results:

  • Observed significant variability in antibody responses to LOS.
  • Some patients developed serotype-specific antibodies, while others showed broader reactivity.
  • Newly developed antibodies targeted both side chain and core LOS structures.

Conclusions:

  • The LOS-based ELISA effectively dissects human antibody responses to M. catarrhalis LOS epitopes.
  • Characterizing these immune responses provides insights for developing effective M. catarrhalis vaccines.